SLC5A2 and hydrops fetalis: We found that ASIs plus β-blockers plus SGLT2 inhibitors vs ASIs were associated with greater effectiveness than ASIs plus β-blockers plus SGLT2 inhibitors vs ASIs plus β-blockers in terms of HF hospitalization, suggesting that β-blockers may be a class of beneficial interferent and that the addition of β-blockers probably led to an incremental benefit for patients with HFpEF or HFmrEF.